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A hallmark of cancer cells is that they are able to
proliferate in the absence of normal proliferative signals.
This self-sufficiency in growth signals is often achieved
through genetic changes that result in the overexpression
of growth factors or their receptors. In breast epithelial
cells, normal proliferation is regulated by both steroid
hormone receptors and the ErbB family of peptide growth
factor receptors (also called Type I receptor tyrosine
kinases or RTKs). Overexpression of these receptors is
frequently found in breast cancer, and identification of the
molecular pathways involved has permitted the develop-
ment of new breast cancer therapies.
Most anti-breast cancer drugs under investigation or in
current use act to inactivate the oestrogen receptor or the
ErbB receptors, ErbB2 and ErbB1. In particular, much
research has focused on the ErbB2 oncogene, because
this gene is frequently overexpressed in breast tumours
and is associated with a poorer prognosis. Now, however,
in a recent report, Holbro and colleagues [1] highlight the
oncogenic potential of another ErbB receptor, the ErbB3
receptor, by showing that ErbB3 functions as an essential
partner of ErbB2 to drive the proliferation of ErbB2-
overexpressing breast tumour cells.
The ErbB family of receptors form homodimers and
heterodimers on ligand binding to the extracellular domain.
The receptor dimer is activated through intrinsic tyrosine
kinase-mediated autophosphorylation of the receptors in
the cytoplasmic domain. These phosphorylations result in
the recruitment of downstream effector proteins that
activate multiple signalling pathways including the
mitogen-activated protein (MAP) kinase and phospho-
inositide 3-kinase (PI-3K) pathways [2–4]. ErbB3 is distinct
in that it has an impaired protein tyrosine kinase activity
and activation of this receptor is achieved only through the
formation of heterodimeric receptor complexes with other
kinase-active family members [5–7]. In this way, the
ErbB2–ErbB3 complex can act as a high-affinity heregulin
co-receptor [8]. The ErbB3 receptor is also unique among
the ErbB family in its ability to directly recruit and activate
PI-3K [5,9].
Elevated levels of tyrosine-phosphorylated ErbB3 are
frequently found in breast tumours that overexpress ErbB2
[10,11]. In addition, in vitro assays in NIH 3T3 cells and a
transgenic mouse model of breast cancer development
have shown that ErbB2 cooperates with ErbB3 to
transform cells [12,13]. This has led to speculation that
ErbB3 might be an important partner to ErbB2 in the
development of breast tumours overexpressing ErbB2. To
address this issue definitively, Holbro and colleagues used
elegant techniques to disrupt ErbB3 and ErbB2 function
selectively in breast cancer cells. They blocked ErbB2
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Abstract
The overexpression of the ErbB family of tyrosine kinase receptors is thought to be important in the
development of many breast tumours. To date, most attention has focused on the ErbB2 receptor.
Now, in a recent report, it has been shown that ErbB3 is a critical partner for the transforming activity
of ErbB2 in breast cancer cells. Importantly, the proliferative signals from this transforming complex
appear to act via the PI-3 kinase pathway.
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activity by using either the ErbB2-selective kinase inhibitor
PKI166 [14] or by functionally inactivating the receptor
through expression of the single-chain antibody scFv-5R,
which targets ErbB2 to the endoplasmic reticulum [15].
To inhibit ErbB3 expression, they infected the cells retro-
virally with an artificial transcription factor, E3, composed
of a polydactyl zinc-finger domain, which specifically
recognizes the 5′ untranslated region of c-erbB3 and
downregulates its expression [16].
With these techniques they demonstrated that ErbB2
inactivation blocked proliferation in ErbB2-overexpressing
cells and that this was associated with a decrease in the
phosphotyrosine content of ErbB3, confirming that ErbB2
activity was required to activate ErbB3. Inactivation of
ErbB2 was also associated with a decrease in the level of
ErbB3–PI-3K complex and the activity of the PI-3K target,
protein kinase B (PKB), demonstrating that activation of
the PI-3K pathway was downstream of this receptor.
Importantly, they found that specific downregulation of the
ErbB3 receptor, using the E3 transcription factor, had
similar antiproliferative effects on the cell lines
overexpressing ErbB2. The specificity of this effect was
confirmed by re-expressing ectopic ErbB3 under the
control of a promoter that was insensitive to the E3
transcription factor. Interestingly, some of the cell lines
tested also express ErbB1 and ErbB4, suggesting that
neither of these receptors is able to substitute for ErbB3.
This idea was confirmed by the observation that re-
expression of ErbB4 was unable to rescue loss of ErbB3.
Together, these results clearly show that ErbB3 is
required for ErbB2 to be transforming in these cells.
Looking at downstream signalling pathways, the authors
observed that, although loss of ErbB3 had no effect on
the levels of signalling through the MAP kinase pathway,
signalling through the PI-3K pathway was blocked in one
cell line. This result suggested that the proliferative signal
from this receptor complex was transmitted via this
pathway. This finding was corroborated by the observation
that constitutive activation of this pathway by the expres-
sion of an active form of PKB was sufficient to overcome
the proliferative arrest seen in response to the loss of
either receptor. Thus, the ErbB2–ErbB3 complex stimulates
an oncogenic, proliferative signal via the PI-3K pathway.
The clear demonstration of the requirement of ErbB3 as a
partner for ErbB2 in breast cell transformation and the
observation that the proliferative drive requires signalling
through the PI-3K pathway are in line with previous
findings. Using a dominant-negative version of ErbB3,
Ram and colleagues reported similar findings that ErbB3
function seemed to be required for the growth factor and
anchorage independence of an ErbB2-overexpressing
breast cancer cell line [17]. In addition, mutagenesis of the
ErbB3 receptor to assess its role in the transformation
ability of the ErbB2–ErbB3 complex in NIH 3T3 cells
points to the importance of the PI-3K pathway in the
induction of cellular transformation [18].
The importance of the PI-3K pathway in breast cancer is
also suggested by the finding of PTEN deletions and
overexpression of PKB in primary breast tumours [19,20].
How does this pathway lead to deregulation of the cell
cycle? Holbro and colleagues show that inactivation of
this pathway is correlated with a loss of cyclin D3
expression and with a decrease in the phosphorylation of
retinoblastoma protein. PI-3K signalling is known to
regulate cyclin D levels at both the transcriptional and
translational levels [21] and is also known to regulate the
concentrations and localization of the cyclin-dependent
kinase inhibitor p27Kip1 [22]. It will be of interest to see
whether these are the signalling pathways responsible for
driving the proliferation of these cells in this context.
These studies clearly show an important role for the PI-3K
pathway in the ability of the ErbB2–ErbB3 complex to
drive proliferation. However, other signalling pathways
originating from the ErbB2–ErbB3 oncogenic unit un-
doubtedly contribute to transformation in vivo. The
ErbB2–ErbB3 heterodimer has been reported to increase
cell motility and to induce morphological changes that
seem to require both PI-3K and MAP kinase signalling
[23]. In addition, the ErbB2–ErbB3 heterodimer has been
reported to upregulate matrix metalloproteinase-9 expres-
sion, which is thought to be important in promoting tumour
invasiveness and metastasis [24]. MAP kinase, p38,
protein kinase C and PI-3K signalling pathways all seem to
have a role in this process. In addition, Src family
signalling is thought to be important in the transformation
process downstream of ErbB2, through regulation of the
cytoskeletal changes that accompany malignant trans-
formation [25].
These findings are relevant to a large proportion of breast
malignancies but might also be useful for our under-
standing of other malignancies. In colorectal cancer, an
increase in ErbB2 expression is often associated with an
increase in ErbB3 expression [26]. Moreover, co-expression
of ErbB2 and ErbB3 is also found in oral squamous cell
carcinoma, ovarian tumours and lung adenocarcinomas
and in many cases seems to be important for the
transformed phenotype of the tumour [27,28].
Advances in our understanding of the molecular pathways
responsible for ErbB-mediated transformation should
result in the development of novel strategies for treating
breast cancer. In particular, the demonstration of an
important role of ErbB3 and the PI-3K pathway in driving
the proliferation of ErbB2-overexpressing breast cancer
cells makes them attractive targets for anti-breast cancer
drugs for this subset of patients. One such drug currently139
undergoing trials is the monoclonal antibody 2C4, which
can disrupt the process of heterodimerisation of the
ErbB2–ErbB3 receptor by hindering the recruitment of
ErbB2 into ErbB3 complexes [29]. It is to be hoped that
the identification of ErbB3 as a requisite component of
ErbB2 signalling will result in the development of further
promising new drugs.
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